Business Context and Reporting Period
Company: AngioDynamics, Inc. (ANGIO)
Filing Type: Form 8-K (Current Report)
Report Date: September 30, 2021
Reporting Period: Fiscal First Quarter ended August 31, 2021
This filing serves to announce the issuance of a press release and presentation slides regarding the company's financial results for the fiscal quarter ended August 31, 2021.
Key Financial Metrics
The provided text is a cover document for the Form 8-K and does not contain specific financial data points. It references a press release (Exhibit 99.1) and presentation slides (Exhibit 99.2) where the actual figures are located.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only confirms that results for the fiscal first quarter ended August 31, 2021, have been announced.
Guidance, Outlook, and Risks
Forward-Looking Statements: The document includes a standard disclaimer that it contains forward-looking statements regarding future financial position, results of operations, and business strategy. These are not guarantees of future performance.
Identified Risks and Uncertainties: The filing lists several factors that could cause actual results to differ materially from expectations:
- Scale and scope of the COVID-19 global pandemic.
- Ability to develop existing and new products.
- Technological advances and patents by competitors.
- Intellectual property infringement claims.
- Competition from entities with greater resources.
- Regulatory actions by the FDA or other agencies.
- Health care reforms and government regulations.
- Results of pending or future clinical trials.
- Overall economic conditions and ongoing litigation.
- Challenges with third-party distributors or joint venture partners.
- Product recalls and product liability claims.
- Changes in key personnel.
- Foreign currency exchange rate fluctuations.
- Pricing effects from group purchasing organizations.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and earnings per share figures for the quarter ended August 31, 2021.
- Review Exhibit 99.2 (Presentation Slides) for management commentary, segment performance, and updated guidance.
- Verify the impact of the COVID-19 pandemic on surgical volumes and product demand as detailed in the full press release.
- Check for any updates on pending litigation or regulatory approvals mentioned in the risk factors.